S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT News Today

$14.06
-0.03 (-0.21%)
(As of 10/5/2022 05:45 PM ET)
Add
Compare
Today's Range
$13.43
$14.28
50-Day Range
$12.21
$19.70
52-Week Range
$10.81
$21.25
Volume
1.00 million shs
Average Volume
965,338 shs
Market Capitalization
$418.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.08
Get Intercept Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.



ICPT Media Mentions By Week

ICPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ICPT
News Sentiment

0.08

0.80

Average
Medical
News Sentiment

ICPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ICPT Articles
This Week

18

2

ICPT Articles
Average Week

SourceHeadline
marketbeat.com logoIntercept Pharmaceuticals, Inc. to Post FY2023 Earnings of ($8.31) Per Share, Oppenheimer Forecasts (NASDAQ:ICPT)
marketbeat.com - October 5 at 7:45 AM
marketbeat.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Short Interest Down 9.7% in September
marketbeat.com - October 2 at 10:52 AM
marketbeat.com logoIntercept Pharmaceuticals (NASDAQ:ICPT) PT Lowered to $49.00 at Piper Sandler
marketbeat.com - September 30 at 11:27 AM
MarketBeat logoIntercept Pharmaceuticals (NASDAQ:ICPT) PT Lowered to $17.00
americanbankingnews.com - October 3 at 7:44 AM
MarketBeat logoIntercept Pharmaceuticals (NASDAQ:ICPT) Given New $49.00 Price Target at Piper Sandler
americanbankingnews.com - October 3 at 2:44 AM
finance.yahoo.com logoInstitutional owners may take dramatic actions as Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) recent 8.5% drop adds to one-year losses
finance.yahoo.com - October 2 at 10:53 AM
reuters.com logoIntercept Pharma's liver disease drug fails late-stage trial
reuters.com - September 30 at 1:49 PM
seekingalpha.com logoIntercept stock slumps 18% as liver disease drug fails phase 3 trial
seekingalpha.com - September 30 at 1:49 PM
marketwatch.com logoIntercept Pharmaceuticals Shares Slide After NASH Study Miss >ICPT
marketwatch.com - September 30 at 1:49 PM
finance.yahoo.com logoIntercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients
finance.yahoo.com - September 30 at 1:49 PM
marketwatch.com logoIntercept Phase 3 Compensated Cirrhosis NASH Study Misses Primary Endpoint >ICPT
marketwatch.com - September 30 at 8:49 AM
finance.yahoo.com logoIntercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
finance.yahoo.com - September 30 at 8:49 AM
finance.yahoo.com logoIntercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
finance.yahoo.com - September 26 at 2:17 PM
markets.businessinsider.com logoB.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)
markets.businessinsider.com - September 22 at 6:40 AM
finance.yahoo.com logoIntercept Pharma Summarizes Key Actions in Strategic Financial Repositioning
finance.yahoo.com - September 21 at 3:37 PM
finance.yahoo.com logoIntercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
finance.yahoo.com - September 21 at 10:37 AM
finance.yahoo.com logoImproved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
finance.yahoo.com - September 20 at 7:33 PM
finance.yahoo.com logoIntercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
finance.yahoo.com - September 7 at 9:46 AM
finance.yahoo.com logoWhy Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?
finance.yahoo.com - September 2 at 3:31 PM
finance.yahoo.com logoIntercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
finance.yahoo.com - August 29 at 3:04 PM
finance.yahoo.com logoImplied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options
finance.yahoo.com - August 29 at 3:04 PM
nasdaq.com logoNoteworthy Tuesday Option Activity: ICPT, IPI, ORCL
nasdaq.com - August 23 at 5:56 PM
markets.businessinsider.com logoRaymond James Maintains Outperform Rating for Intercept Pharmaceuticals: Here's What You Need To Know
markets.businessinsider.com - August 22 at 2:02 PM
markets.businessinsider.com logoWhat 6 Analyst Ratings Have To Say About Intercept Pharmaceuticals
markets.businessinsider.com - August 22 at 2:02 PM
benzinga.com logoCheck Out What Whales Are Doing With ICPT
benzinga.com - August 19 at 3:50 PM
finance.yahoo.com logoIntercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
finance.yahoo.com - August 18 at 1:31 PM
finance.yahoo.com logoIntercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
finance.yahoo.com - August 18 at 8:31 AM
seekingalpha.com logoIntercept, Dr. Reddy’s settle patent dispute over Oclaiva generics
seekingalpha.com - August 17 at 5:29 PM
investing.com logoIntercept Pharmaceuticals PT Lowered to $16 at H.C. Wainwright
investing.com - August 8 at 6:59 AM
finance.yahoo.com logoIntercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
finance.yahoo.com - August 5 at 8:25 AM
markets.businessinsider.com logoWhere Intercept Pharmaceuticals Stands With Analysts
markets.businessinsider.com - August 4 at 4:07 PM
finance.yahoo.com logoIntercept (ICPT) Earnings and Sales Miss Estimates in Q2
finance.yahoo.com - August 4 at 11:06 AM
seekingalpha.com logoIntercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 3:55 PM
finance.yahoo.com logoIntercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - August 3 at 10:40 AM
finance.yahoo.com logoIntercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 3 at 10:40 AM
morningstar.com logoIntercept Pharmaceuticals Inc Stock News
morningstar.com - July 29 at 4:55 AM
finance.yahoo.com logoIntercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
finance.yahoo.com - July 27 at 11:29 AM
finance.yahoo.com logoNeedham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path
finance.yahoo.com - July 8 at 9:06 PM
finance.yahoo.com logoThe NASH Drug Dream Isn’t Dead Yet. Intercept is Asking FDA for Approval Again.
finance.yahoo.com - July 8 at 4:05 PM
finance.yahoo.com logoIntercept (ICPT) Reports Positive Data From NASH Study on OCA
finance.yahoo.com - July 8 at 4:05 PM
reuters.com logoIntercept to go back to FDA with its NASH treatment application
reuters.com - July 8 at 4:48 AM
markets.businessinsider.com logoIntercept Shares Fall After Interim Analysis On Late-Stage NASH Study
markets.businessinsider.com - July 7 at 6:43 PM
nasdaq.com logoIntercept to resubmit NASH treatment application for FDA review
nasdaq.com - July 7 at 6:43 PM
seekingalpha.com logoIntercept to resubmit for FDA approval of NASH candidate after new analysis
seekingalpha.com - July 7 at 6:43 PM
finance.yahoo.com logoUPDATE 2-Intercept to go back to FDA with its NASH treatment application
finance.yahoo.com - July 7 at 6:43 PM
finance.yahoo.com logoIntercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
finance.yahoo.com - July 7 at 6:43 PM
marketwatch.com logoIntercept Reports More Positive Phase 3 Data From NASH Study >ICPT
marketwatch.com - July 7 at 8:03 AM
finance.yahoo.com logoIntercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
finance.yahoo.com - July 7 at 8:03 AM
finance.yahoo.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
finance.yahoo.com - June 24 at 4:00 PM
finance.yahoo.com logoIntercept Announces PBC Data Presentations at The International Liver Congress™ 2022
finance.yahoo.com - June 21 at 11:14 AM
finance.yahoo.com logoIntercept Announces PBC Data Presentations at The International Liver Congress™ 2022
finance.yahoo.com - June 21 at 11:14 AM
seekingalpha.com logoIntercept announces delay for key FDA meeting ahead of filing for NASH candidate
seekingalpha.com - June 6 at 8:25 AM
finance.yahoo.com logoIntercept Provides Update on NASH Regulatory Timeline
finance.yahoo.com - June 6 at 8:25 AM
Get Intercept Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ICPT) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.